Multidisciplinary

Access to gender-affirming care reduces depression, suicidality in transgender, non-binary youth

Receipt of gender-affirming care reduces depression, suicidality in transgender, non-binary youth

Roshini Claire Anthony, 13 hours ago

Receipt of gender-affirming care led to a reduced risk of depression and suicidality among transgender and non-binary (TNB) youth, according to a prospective study presented at the American Academy of Pediatrics 2021 National Conference & Exhibition (AAP 2021).

Switching to TAF helps improve virologic response in HBV patients in real world

Pearl Toh, 15 hours ago

Switching to tenofovir alafenamide (TAF) from nucleos(t)ide analogue therapies was associated with improved virologic response and liver function in patients with chronic hepatitis B virus (HBV) infection, even in those with decompensated HBV cirrhosis, according to real-world studies presented at AASLD 2021.

Birth control pills pose inflammatory bowel disease risk

Jairia Dela Cruz, 15 hours ago

The use of combined oral contraceptive pills (COCPs) appears to confer some risk of inflammatory bowel disease, which increases accordingly with duration of COCP exposure, as shown in a study.

$Continuous smartphone use tied to refractive error in teens$

Continuous smartphone use tied to refractive error in teens

Stephen Padilla, 17 hours ago

A recent study involving Dutch teenagers has found that a higher number of episodes of >20 minutes of continuous smartphone use may lead to more myopic refractive errors. Such association does not exist in those with high outdoor exposure.

Diabetes complications and the importance of early diabetes screening

01 Dec 2021

It has been estimated that diabetes – a chronic metabolic disorder resulting in hyperglycaemia – affects 422 million adults globally.1 In 2019, the disease caused 1.5 million deaths worldwide and the number of people with diabetes is expected to reach 642 million by 2040.

Taking the big leapfrog to advance T2D care

01 Dec 2021

During the Guardians for Health Summit 2021 supported by Boehringer Ingelheim, several distinguished speakers shared their insights into the importance of type 2 diabetes (T2D) guideline adherence and patient empowerment, as well as the impact of clinical inertia on the burden of cardiorenal metabolic diseases.

EMPEROR-Preserved: The first successful trial to improve outcomes in HFpEF

18 Nov 2021

Heart failure with preserved ejection fraction (HFpEF) represents a significant unmet medical need. The EMPEROR-Preserved trial aimed to assess the impact of empagliflozin on cardiovascular outcomes in patients with HFpEF. On 27 August 2021, during the hotline session of the 2021 ESC Virtual Congress, the main results of the EMPEROR-Preserved trial were presented by Professor Stefan Anker, principal investigator of the study, and heart failure specialist at Charité Berlin, Germany.

NOACs in nonvalvular atrial fibrillation with multimorbidity: Where does apixaban stand?

02 Nov 2021

Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice, affecting millions of people globally. Stroke is one of its devastating complications, with the risk steeply increasing with advancing age. Additionally, AF is associated with more than a tripling of the risk of systemic embolic (SE) events. [J Am Heart Assoc 2020;9:e016724]

Switching to TAF helps improve virologic response in HBV patients in real world

Pearl Toh, 06 Dec 2021

Interim findings boost therapeutic potential of lanifibranor for NASH

Audrey Abella, 06 Dec 2021

The pan-PPAR* agonist lanifibranor further advances into the NASH** treatment field, as more data from the phase IIb NATIVE*** study presented at AASLD 2021 unveil further histologic and therapeutic benefits for patients with NASH.

Empagliflozin beneficial and well tolerated in acute heart failure

Christina Lau, 06 Dec 2021

Empagliflozin provides a significant clinical benefit within 90 days and shows no safety concerns in patients hospitalized for acute heart failure (HF), according to results of the EMPULSE trial reported at the American Heart Association (AHA) Scientific Sessions 2021.

Canagliflozin improves HF symptoms, QoL regardless of diabetes status

Pearl Toh, 04 Dec 2021

The SGLT2i* canagliflozin significantly improves symptoms and quality of life (QoL) early on during treatment in people with heart failure (HF) due to either reduced or preserved ejection fraction (rEF or pEF), regardless of whether they have type 2 diabetes (T2D), according to the CHIEF-HF** study presented at AHA 2021.

Non-overweight NAFLD patients have poor liver transplant outcomes

Roshini Claire Anthony, 03 Dec 2021

Non-overweight patients with non-alcoholic fatty liver disease (NAFLD) have an elevated risk of all-cause mortality following liver transplant and are also more likely to be removed from the liver transplant waitlist compared with obese/overweight patients, according to a study presented at The Liver Meeting Digital Experience™.

Inclisiran sustains LDL-C reduction in high-risk patients for ASCVD

Elaine Soliven, 03 Dec 2021

Treatment with inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) levels in patients with, or at high risk of, atherosclerotic cardiovascular disease (ASCVD), regardless of glycaemic status, based on a pooled analysis of the ORION-10* and ORION-11** studies presented at AHA 2021.

Milvexian prevents VTE after knee arthroplasty, bleeding risk low

Roshini Claire Anthony, 02 Dec 2021

Postoperative treatment with the oral factor XIa inhibitor milvexian could help prevent the incidence of venous thromboembolism (VTE) in patients undergoing elective knee arthroplasty, according to results of a phase II trial presented at AHA 2021.